PAREXEL International Corporation (PRXL) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of PAREXEL International Corporation (NASDAQ:PRXL) from a hold rating to a buy rating in a research report released on Saturday. They currently have $98.00 price target on the medical research company’s stock.
According to Zacks, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. “
Several other research firms have also commented on PRXL. BidaskClub lowered PAREXEL International Corporation from a strong-buy rating to a buy rating in a report on Friday, July 28th. Jefferies Group LLC reaffirmed a hold rating and set a $88.10 target price on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Barclays PLC lowered PAREXEL International Corporation from an overweighr rating to an equal weight rating and set a $87.00 target price on the stock. in a report on Tuesday, June 20th. Raymond James Financial, Inc. raised PAREXEL International Corporation from an underperform rating to a mkt perform rating in a report on Tuesday, June 20th. Finally, Credit Suisse Group reaffirmed a neutral rating and set a $83.00 target price (up from $65.00) on shares of PAREXEL International Corporation in a report on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $75.93.
Shares of PAREXEL International Corporation (PRXL) traded up 0.02% on Friday, hitting $87.66. The company had a trading volume of 721,498 shares. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.86. The company has a market capitalization of $4.45 billion, a price-to-earnings ratio of 38.53 and a beta of 0.79. The stock’s 50-day moving average is $87.43 and its 200 day moving average is $74.60.
ILLEGAL ACTIVITY NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/20/parexel-international-corporation-prxl-upgraded-by-zacks-investment-research-to-buy.html.
A number of hedge funds have recently modified their holdings of PRXL. Capstone Asset Management Co. raised its stake in shares of PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock valued at $278,000 after buying an additional 160 shares during the last quarter. Clinton Group Inc. acquired a new stake in shares of PAREXEL International Corporation during the first quarter valued at approximately $3,682,000. LSV Asset Management raised its stake in shares of PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock valued at $24,029,000 after buying an additional 116,200 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in shares of PAREXEL International Corporation during the fourth quarter valued at approximately $789,000. Finally, Gabelli Funds LLC acquired a new stake in shares of PAREXEL International Corporation during the first quarter valued at approximately $1,136,000. 91.58% of the stock is currently owned by institutional investors.
About PAREXEL International Corporation
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.